Skip to main content

Table 6 Chronological listing of withdrawals

From: Study of Optimal Replacement of Thyroxine in the Elderly (SORTED) – results from the feasibility randomised controlled trial

Subject ID

Treatment allocation

Randomisation date

Withdrawal date

Days in the study

Reason (severity and relation to study drug)

709

Reduced dose

07/12/2012

09/01/2013

34

Withdrew due to AEs experienced whilst on the study: constipation, tiredness and generally unwell (mild, possibly related)

103

Usual dose

11/01/2013

23/01/2013

13

Withdrew due to “feeling unwell” (mild, possibly related)

104

Reduced dose

11/01/2013

27/03/2013

76

Withdrew due to infected right foot (moderate, not related), loose stools (moderate, unknown relationship to study drug) and sore wrist (mild, unknown relationship to study drug)

509

Reduced dose

26/11/2012

22/04/2013

148

6 weeks after Visit 2 withdrew from the study due to tiredness (moderate, possibly related)

205

Usual dose

01/03/2013

22/04/2013

53

Withdrew due to fatigue which started 2 weeks after commencing the study drug. The patient was hospitalised with a mild stroke on 22/04/13, reported to be linked to ongoing hypertension (severe, not related).

515

Reduced dose

18/02/2013

08/05/2013

80

Withdrew after experiencing several AEs: dry skin, dry hair, feeling cold, weight gain and tiredness (mild, possibly related), and swollen face with itching (mild, not related) - unscheduled home visit: thyroid function normal, weight gain of 0.3kgs.

521

Reduced dose

15/05/2013

12/06/2013

29

Withdrew after experiencing several AEs: nausea and loss of appetite (mild, not related), vertigo (mild, not related) and confusion (mild, not related)

614

Usual dose

20/03/2013

27/06/2013

100

At Visit 2 patient reported that she had been taking her prescribed dose of LT4 as well as the study medication. Patient reported no AEs. Serum thyroid function was normal (TSH 0.60, FT4 20.8). Subsequently the patient changed her mind and withdrew.

  1. AEs adverse events, LT4 levothyroxine